Search for drugs:
Typing the drug name to query
ELTROMBOPAG OLAMINE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At doses up to 150 mg (the maximum recommended dose) daily for 5 days, PROMACTA did not prolong the QT/QTc interval to any relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
4
24088
Other ADRs
34314
38347273
Odds Ratio = 0.186
Drug Property Information
ATC Code(s):
- B02BX05 - eltrombopag olamine
- B02BX - Other systemic hemostatics
- B02B - VITAMIN K AND OTHER HEMOSTATICS
- B02 - ANTIHEMORRHAGICS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:ELTROMBOPAG OLAMINE
Active Ingredient UNII:4U07F515LG
Drugbank ID:DB06210
PubChem Compound:9846180
CAS Number:496775-61-2
Dosage Form(s):powder, for suspension; tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 50.0 mg/day B02BX05
Chemical Structure: 
SMILE Code:
CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1
CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.